{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:48:47Z","timestamp":1790682527675,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.ygyno.2012.09.016","type":"journal-article","created":{"date-parts":[[2012,9,23]],"date-time":"2012-09-23T10:01:32Z","timestamp":1348394492000},"page":"579-586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer"],"prefix":"10.1016","volume":"127","author":[{"given":"Andrew J.","family":"Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anum S.","family":"Lalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Wass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Saskowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dineo","family":"Khabele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2012.09.016_bb0005","first-page":"10","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ygyno.2012.09.016_bb0010","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ygyno.2008.09.034","article-title":"Platinum compounds 30years after the introduction of cisplatin: implications for the treatment of ovarian cancer","volume":"112","author":"Muggia","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"7353","key":"10.1016\/j.ygyno.2012.09.016_bb0190","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"TCGA","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ygyno.2012.09.016_bb0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ygyno.2012.09.016_bb0195","doi-asserted-by":"crossref","first-page":"484","DOI":"10.4161\/cbt.12.6.15956","article-title":"The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells","volume":"12","author":"Wilson","year":"2011","journal-title":"Cancer Biol Ther"},{"issue":"17","key":"10.1016\/j.ygyno.2012.09.016_bb0030","first-page":"4916","article-title":"FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases","volume":"62","author":"Furumai","year":"2002","journal-title":"Cancer Res"},{"issue":"32","key":"10.1016\/j.ygyno.2012.09.016_bb0035","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ygyno.2012.09.016_bb0200","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ygyno.2012.09.016_bb0205","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/nrc2523","article-title":"GammaH2AX and cancer","volume":"8","author":"Bonner","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ygyno.2012.09.016_bb0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2407-10-4","article-title":"Residual gammaH2AX foci as an indication of lethal DNA lesions","volume":"10","author":"Banath","year":"2010","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2012.09.016_bb0210","doi-asserted-by":"crossref","first-page":"795","DOI":"10.4161\/cbt.6.5.4007","article-title":"Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy","volume":"6","author":"Khabele","year":"2007","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"10.1016\/j.ygyno.2012.09.016_bb0060","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1158\/1535-7163.MCT-08-0921","article-title":"DNA fingerprinting of the NCI-60 cell line panel","volume":"8","author":"Lorenzi","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.ygyno.2012.09.016_bb0065","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/1535-7163.MCT-06-0433","article-title":"Mutation analysis of 24 known cancer genes in the NCI-60 cell line set","volume":"5","author":"Ikediobi","year":"2006","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.ygyno.2012.09.016_bb0070","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/jnci\/90.11.862","article-title":"Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen","volume":"90","author":"Scudiero","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ygyno.2012.09.016_bb0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1541-7786.MCR-06-0234","article-title":"Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation","volume":"5","author":"DelloRusso","year":"2007","journal-title":"Mol Cancer Res"},{"issue":"13","key":"10.1016\/j.ygyno.2012.09.016_bb0215","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2012.09.016_bb0085","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"issue":"2","key":"10.1016\/j.ygyno.2012.09.016_bb0220","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/clpt.2008.200","article-title":"Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients","volume":"85","author":"Rubio-Viqueira","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.ygyno.2012.09.016_bb0095","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1091\/mbc.e08-02-0139","article-title":"HDAC4 promotes growth of colon cancer cells via repression of p21","volume":"19","author":"Wilson","year":"2008","journal-title":"Mol Biol Cell"},{"issue":"17","key":"10.1016\/j.ygyno.2012.09.016_bb0100","first-page":"5401","article-title":"TR3\/Nur77 in colon cancer cell apoptosis","volume":"63","author":"Wilson","year":"2003","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ygyno.2012.09.016_bb0225","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1757-2215-5-12","article-title":"Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy","volume":"5","author":"Wilson","year":"2012","journal-title":"J Ovarian Res"},{"issue":"11","key":"10.1016\/j.ygyno.2012.09.016_bb0230","doi-asserted-by":"crossref","first-page":"928","DOI":"10.4161\/cbt.9.11.11873","article-title":"The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21","volume":"9","author":"Son","year":"2010","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"10.1016\/j.ygyno.2012.09.016_bb0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.molcel.2008.02.030","article-title":"Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control","volume":"30","author":"Bhaskara","year":"2008","journal-title":"Mol Cell"},{"issue":"11","key":"10.1016\/j.ygyno.2012.09.016_bb0235","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1158\/0008-5472.CAN-09-3028","article-title":"Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage","volume":"70","author":"Conti","year":"2010","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ygyno.2012.09.016_bb0240","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ccr.2010.10.022","article-title":"Hdac3 is essential for the maintenance of chromatin structure and genome stability","volume":"18","author":"Bhaskara","year":"2010","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.ygyno.2012.09.016_bb0130","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1349-7006.2007.00669.x","article-title":"Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs","volume":"99","author":"Ozaki","year":"2008","journal-title":"Cancer Sci"},{"issue":"18","key":"10.1016\/j.ygyno.2012.09.016_bb0245","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.4161\/cc.10.18.17190","article-title":"Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer","volume":"10","author":"Luchenko","year":"2011","journal-title":"Cell Cycle"},{"issue":"12","key":"10.1016\/j.ygyno.2012.09.016_bb0250","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1158\/1078-0432.CCR-08-2786","article-title":"Rational combinations using HDAC inhibitors","volume":"15","author":"Bots","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ygyno.2012.09.016_bb0145","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ygyno.2010.06.030","article-title":"In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?","volume":"119","author":"Modesitt","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"33","key":"10.1016\/j.ygyno.2012.09.016_bb0255","doi-asserted-by":"crossref","first-page":"14639","DOI":"10.1073\/pnas.1008522107","article-title":"Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair","volume":"107","author":"Lee","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.ygyno.2012.09.016_bb0260","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1124\/jpet.105.083956","article-title":"Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithi a-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines","volume":"314","author":"Xiao","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.ygyno.2012.09.016_bb0265","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/jpet.104.072033","article-title":"Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1","volume":"313","author":"Xiao","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.ygyno.2012.09.016_bb0165","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/blood-2004-10-4126","article-title":"Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells","volume":"107","author":"Tabe","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ygyno.2012.09.016_bb0270","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3892\/ijo.2010.879","article-title":"HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization","volume":"38","author":"Kim","year":"2011","journal-title":"Int J Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2012.09.016_bb0275","first-page":"402","article-title":"Anti-tumor activity of histone deacetylase inhibitors and the effect on ATP-binding cassette in ovarian carcinoma cells","volume":"31","author":"Chao","year":"2010","journal-title":"Eur J Gynaecol Oncol"},{"issue":"11","key":"10.1016\/j.ygyno.2012.09.016_bb0280","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-08-2048","article-title":"Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes","volume":"15","author":"Hauswald","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ygyno.2012.09.016_bb0185","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1158\/1541-7786.MCR-07-0175","article-title":"Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells","volume":"6","author":"To","year":"2008","journal-title":"Mol Cancer Res"},{"issue":"5","key":"10.1016\/j.ygyno.2012.09.016_bb0285","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1158\/1078-0432.CCR-05-1423","article-title":"Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176)","volume":"12","author":"Robey","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581200772X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581200772X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:33:14Z","timestamp":1758771194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581200772X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S009082581200772X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.09.016","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}